Blue Jet Health
Blue Jet Health Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #23 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Blue Jet Health Q1 FY27 key numbers
- Revenue
- Incremental sales of INR30 crores likely to be recognized next quarter, subject to goods in transit variances.
As stated in Blue Jet Health's Q1 FY27 earnings call transcript · published 25 Aug 2026. Reported figures, not investment advice.
The short version
Robust order book and strong visibility for the next several quarters, especially in PI/API segment. Blue Jet Healthcare expects sustained strong revenue growth in PI/API segment for next 3-4 quarters due to secular growth and strong order book (Page 8).
From Blue Jet Health's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Robust order book and strong visibility for the next several quarters, especially in PI/API segment.
- Incremental sales of INR30 crores likely to be recognized next quarter, subject to goods in transit variances.
- 3 candidates expected to launch in FY27 in Contrast Media; ongoing pilot for high-intensity sweetener.
- 20+ high conviction NCE RFPs being tracked with potential materialization of ~20%.
- Expectation of at least 2 lateral entry programs to fructify in near to medium term with initial clinical/validation quantities.
- Capacity expansion at Vizag and Mahad projects will support growth in complex APIs and CDMO manufacturing.
- Sustainable secular growth in PI/API tied to strong prescription market and consistent order book.
2 more points from Blue Jet Health's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Blue Jet Health said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Mahad Facility: Investment of about INR210 crores already spent, with an additional INR40 crores committed to complete this phase. It is a globally scaled manufacturing facility for contrast media intermediates, expected to commission later in 2026, enhancing supply security and vertical integration.
- Vizag Facility: Secured ~100 acres, planning Phase 1 investment of ~INR1,000 crores over 3 years, focusing on expanding contrast media manufacturing, multipurpose finishing blocks, flexible capacities for lateral entries, high-intensity sweetener production, and intermediate clusters. Consent to establish obtained and preconstruction activities underway.
- R&D Center: New facility with focus on peptides, GLP-1 intermediates, biocatalysts, continuous manufacturing, flow synthesis, and complex synthetic pathways. First phase expected operational by August 2026, strengthening CDMO capabilities and accelerating customer responsiveness.
- FY27 Capex Guidance: Around INR400 crores planned, consistent with prior guidance.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Blue Jet Health said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Blue Jet Healthcare Limited has a robust order book with good visibility for the next several quarters.
- The company is tracking approximately 20 high-conviction RFPs (Request for Proposals), mostly in the chronic therapy space, with the potential for diversification beyond the current portfolio.
- Of these 20 high-conviction opportunities, around 20% are expected to materialize into business.
- New opportunities include 4 programs progressing well with innovator companies, alongside existing commercial orders.
- The cardiovascular (PI/API) segment has strong order books and steady production visibility for at least the next 3-4 quarters.
2 more points from Blue Jet Health's call on order book
Create a free account to keep reading this call
What the Q1 FY27 call signalled
3 of 4 strong
Blue Jet Health — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹235 Cr, net profit ₹64 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Blue Jet Health's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Blue Jet Health and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Blue Jet Health Q1 FY27 results?
Robust order book and strong visibility for the next several quarters, especially in PI/API segment. Blue Jet Healthcare expects sustained strong revenue growth in PI/API segment for next 3-4 quarters due to secular growth and strong order book (Page 8).
What is Blue Jet Health share price analysis?
Blue Jet Health currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 48.0 with a market cap of ₹11,284 Cr. Investors should review the full earnings analysis for detailed insights.
Is Blue Jet Health planning capital expenditure?
Mahad Facility: Investment of about INR210 crores already spent, with an additional INR40 crores committed to complete this phase.
Keep Blue Jet Health on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.